Hong Kong stock movement: INNOGEN-B rose by 19.44%, with clear capital flow, market sentiment triggered volatility attention

Hong Kong Stock Movement INNOGEN-B rose 19.44%, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry PAG Biopharma-B rose 11.77%, with a trading volume of HKD 380 million, and no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Innovent Biologics rose 0.12%. Based on recent key news: On May 18, Innovent Biologics announced its latest R&D progress, focusing on drug production for tumors, cardiovascular, and metabolic diseases. This news has enhanced market confidence in its future growth, driving the stock price up. Source: Innovent Biologics official announcement On May 19, Innovent Biologics released related content through PR Newswire, emphasizing its business development under competitive environments and political-economic conditions. This move further solidified investors' confidence in the company's strategy. Source: PR Newswire On May 19, Innovent Biologics mentioned in its official statement that future business changes may lead to actual results differing from expectations; nevertheless, the market remains optimistic about its long-term development. Source: Innovent Biologics official announcement. The biopharmaceutical industry has performed strongly recently, with significant capital inflow. Kangfang Biologics fell 0.62%, with a trading volume of HKD 230 million, and no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Market Capitalization in the Industry BeiGene rose 0.63%. Based on recent key news: On May 14, BeiGene announced that its drug, Tisotumab vedotin, received FDA accelerated approval for the treatment of relapsed or refractory mantle cell lymphoma. This approval marks the first new BCL2 inhibitor approved in the U.S. in a decade, driving BeiGene's stock price up. Source: Zhitong Finance On May 11, Citigroup released a research report, pointing out that BeiGene's Q1 performance was strong, with total revenue exceeding estimates by 5%, and raised its full-year revenue guidance. Citigroup maintained a "Buy" rating and raised the target price for U.S. stocks to $453, enhancing market confidence. Source: Zhitong Finance On May 18, BeiGene's innovative layout in the solid tumor field has attracted widespread attention, providing a new growth curve for early pipelines such as Tisotumab vedotin, further solidifying its market position. Source: Wall Street Insight. The global pharmaceutical industry is facing intensified competition, highlighting the value of innovative drugs